All In Biotech

Drug Trial Radar · NCT07814417

A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Olomorasib in Combination With Cetuximab and mFOLFOX6 in Participants With KRAS G12C-Mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Nov 2028

Study completion Nov 2028

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Sep 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate how well olomorasib is tolerated and what side effects may occur when combined with other interventions in participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutant, locally advanced colorectal cancer (CRC) that cannot be removed with surgery or has spread to other parts of the body. Blood tests will be performed to investigate how the body processes the study drug.

Conditions

  • Colorectal Neoplasms

Interventions

  • OlomorasibDrug

    Administered orally

  • CetuximabDrug

    Administered IV

  • OxaliplatinDrug

    Administered IV

  • Leucovorin/levofolinate calciumDrug

    Administered IV

  • 5-fluorouracilDrug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Baseline until Disease Progression (PD) or Participant Stops Study (Estimated up to 15 Months)
  2. Progression-Free Survival (PFS) Per RECIST v1.1Time frame: Baseline to the Date of First Documented Progression of Disease or Participant Stops Study (Estimated up to 21 Months)

Locations

18 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • AdventHealth Orlando

    Orlando, Florida

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • START Astera, LLC

    East Brunswick, New Jersey

  • Texas Oncology - Central South

    Austin, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Inova Health Care Services

    Falls Church, Virginia

  • University of Wisconsin - Carbone Cancer Center

    Madison, Wisconsin

  • Beijing Cancer hospital

    Beijing, China

  • Hospital del Mar

    Barcelona, Spain

  • Hospital Universitari Quiron Dexeus Barcelona

    Barcelona, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Complejo hospitalario de Jaen

    Jaén, Spain

  • Clinica Universidad de Navarra - Madrid

    Madrid, Spain

  • Hospital Universitario de Canarias

    Santa Cruz de Tenerife, Spain

  • Hospital Universitario Marques De Valdecilla

    Santander, Spain

  • Hospital Clinico Universitario de Santiago

    Santiago de Compostela, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.